Anti-Insulin Affibody® Molecule (ab31906)
製品の概要
-
製品名
Anti-Insulin Affibody® Molecule -
アプリケーション
適用あり: IHC-Fr, IHC-Pmore details -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Recombinant full length protein corresponding to Insulin.
-
特記事項
ab31906 is a recombinant protein produced in E. coli.
What are Affibody Molecules?
Affibody® affinity ligands are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A. Protein A is a surface protein from the bacterium Staphylococcus aureus. This scaffold has excellent features as an affinity ligand and can be designed to bind with high affinity to any given target protein. The domain consists of 58 amino acids, 13 of which are randomized to generate Affibody® libraries with a large number of ligand variants. Thus, the libraries consist of a multitude of protein ligands with an identical backbone and variable surface- binding properties. The current Affibody® libraries contains billions of variants. In function, Affibody® molecules mimic antibodies, nature’s own binders to an infinite number of antigens. Compared to antibodies, the most striking dissimilarity of Affibody® molecules is the small size. Affibody® molecules have a molecular weight of 14 kDa, compared to the molecular weight of antibodies, which is 150 kDa. In spite of its small size, the binding site of Affibody® molecules is similar to that of an antibody. The advantages of Affibody® molecules over antibodies are · their small size · the simple structure of the molecules · its robust physical properties · its ability to fold correctly intracellularly · the fast and cost-efficient production in bacteria · the possibility to produce Affibody® molecules through chemical synthesis · the possibility to couple Affibody® molecules in multimeric constructs.This Anti-Insulin Affibody® Molecule is modified with a unique C-terminal cysteine for directed single-point chemical modification, facilitating labelling with fluorescent dyes, biotin or coupling to matrices. However, tail-to-tail dimers are spontaneously generated via a disulphide bridge between the C-terminal cysteines. Prior to coupling via the C-terminal the Affibody® Molecule needs to be reduced to expose the reactive cysteine residue. Recommended reducing condition is 20mM DTT at a pH above 7.5 and incubation at room temperature for 2 hours. Remove excess DTT by passage through a desalting column, not by dialysis. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
THIS AFFIBODY® MOLECULE REQUIRES CONJUGATION TO A SUITABLE LABEL BEFORE USE. PLEASE REFER TO THE "PROTOCOLS" LINK BELOW.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
バッファー
pH: 7.40
Constituent: 0.079% Ammonium bicarbonate -
Concentration information loading...
-
特記事項(精製)
ab31906 is >98% pure, as determined by SDS-PAGE (Coomassie blue staining) and RP-HPLC analysis. -
研究分野
-
機能
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. -
関連疾患
Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].
Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.
Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. -
配列類似性
Belongs to the insulin family. -
細胞内局在
Secreted. - Information by UniProt
-
別名
- IDDM
- IDDM1
- IDDM2
see all -
参照データベース
- Entrez Gene: 3630 Human
- Entrez Gene: 16333 Mouse
- Entrez Gene: 24505 Rat
- Omim: 176730 Human
- SwissProt: P01308 Human
- SwissProt: P01325 Mouse
- SwissProt: P01322 Rat
- Unigene: 272259 Human
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab31906の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IHC-P |
Use at an assay dependent concentration.
|
|
AP |
Use at an assay dependent concentration.
|
特記事項 |
---|
IHC-Fr
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
AP
Use at an assay dependent concentration. |
画像
-
To demonstrate the binding capacity and specificity of the Anti-Insulin Affibody® molecule, 1.5 ml of five times diluted human serum spiked with insulin was injected on a column with 0.4 ml SulfoLink® Coupling gel with immobilized Anti-Insulin Affibody® molecule.
To demonstrate the binding capacity and specificity of the Anti-Insulin Affibody® molecule, 1.5 ml of five times diluted human serum spiked with insulin was injected on a column with 0.4 ml SulfoLink® Coupling gel with immobilized Anti-Insulin Affibody® molecule. -
Eluted and flow-through fractions were analyzed by an SDS-PAGE analysis:
Lane 1: human serum spiked with insulin
Lane 2: flowthrough fraction
Lane 3: eluted fraction
Lane 4: human insulin standard
Eluted and flow-through fractions were analyzed by an SDS-PAGE analysis:
Lane 1: human serum spiked with insulin
Lane 2: flowthrough fraction
Lane 3: eluted fraction
Lane 4: human insulin standard
データシートおよび資料
-
SDS download
-
Datasheet download
プロトコール
参考文献 (3)
ab31906 は 3 報の論文で使用されています。
- Luckett BS et al. Arcuate nucleus injection of an anti-insulin affibody prevents the sympathetic response to insulin. Am J Physiol Heart Circ Physiol 304:H1538-46 (2013). PubMed: 23542919
- Paranjape SA et al. Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 59:1521-7 (2010). PubMed: 20299468
- McNay EC et al. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem 93:546-53 (2010). Other . PubMed: 20176121